Experts are advocating for a common women's health condition to be renamed in a move they hope will reduce misdiagnoses and stigma. Polycystic ovarian syndrome (PCOS), which affects approximately one in eight women, is a complex, long-term hormonal disorder that can impact weight, skin, metabolism, mental health, and the reproductive system.
New Name Proposed
A new consensus statement published in The Lancet proposes the name polyendocrine metabolic ovarian syndrome (PMOS). The change aims to better reflect the condition's multi-system pathophysiology, moving away from the current name which critics say implies 'pathological ovarian cysts' and obscures the diverse endocrine and metabolic features.
Impact on Diagnosis and Care
The current name has been blamed for contributing to delayed diagnoses and misunderstanding. Experts argue that the term PCOS leads to fragmented care and stigma, as it focuses solely on the ovaries rather than the broader systemic nature of the condition. The new name, PMOS, is intended to highlight the endocrine and metabolic aspects, which are central to the disorder.
PCOS can cause chronic pelvic pain, irregular periods, fertility issues, and increased risk of type 2 diabetes and heart disease. By renaming the condition, experts hope to improve awareness, diagnosis, and treatment.
Support and Next Steps
NHS officials have confirmed they will 'carefully consider' the recommendation, which has garnered support from academics, patient groups, and clinical organisations. The proposal is part of a broader effort to improve outcomes for women with the condition.
- PCOS affects around one in eight women in the UK.
- The new name PMOS emphasises polyendocrine and metabolic features.
- Experts believe the change could reduce misdiagnoses and stigma.
